Raleigh Capital Management Inc. Amgen Inc Transaction History

Raleigh Capital Management Inc.

$255 Million
Q3 2024

A detailed history of Raleigh Capital Management Inc. transactions in Amgen Inc stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 3,702 shares of AMGN stock, worth $972,330. This represents 0.47% of its overall portfolio holdings.

Number of Shares

3,702

Previous 5,867 36.9%

Holding current value

$972,330

Previous $1.83 Million 34.97%

% of portfolio

0.47%

Previous 0.79%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$309.38 - $337.38 $669,807 - $730,427	-2,165 Reduced 36.9%	3,702 $1.19 Million
Q2 2024 Jul 31, 2024	BUY	$262.75 - $319.31 $266,165 - $323,461	1,013 Added 20.87%	5,867 $1.83 Million
Q1 2024 May 13, 2024	SELL	$268.87 - $324.56 $345,229 - $416,735	-1,284 Reduced 20.92%	4,854 $1.38 Million
Q4 2023 Feb 21, 2024	SELL	$255.7 - $288.46 $814,660 - $919,033	-3,186 Reduced 34.17%	6,138 $1.77 Million
Q3 2023 Dec 06, 2023	BUY	$218.65 - $271.46 $112,823 - $140,073	516 Added 5.86%	9,324 $2.51 Million
Q2 2023 Jul 25, 2023	BUY	$214.27 - $253.37 $641,738 - $758,843	2,995 Added 51.52%	8,808 $1.96 Million
Q1 2023 May 22, 2023	BUY	$225.79 - $275.2 $463,095 - $564,435	2,051 Added 54.52%	5,813 $1.41 Million
Q4 2022 Feb 07, 2023	SELL	$229.03 - $291.01 $866,878 - $1.1 Million	-3,785 Reduced 50.15%	3,762 $988,000
Q3 2022 Nov 09, 2022	BUY	$224.46 - $253.15 $674,726 - $760,968	3,006 Added 66.2%	7,547 $1.7 Million
Q2 2022 Aug 30, 2022	BUY	$230.71 - $256.74 $296,693 - $330,167	1,286 Added 39.51%	4,541 $1.11 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $713,723 - $789,565	3,255 New	3,255 $787,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.

Account

Raleigh Capital Management Inc. Amgen Inc Transaction History